Experimental drug tested for Tough-to-Treat cancers
NCT ID NCT06171789
Summary
This early-phase study tested a new drug called PRO1107 in patients with advanced solid tumors that had stopped responding to other treatments. The main goals were to find a safe dose and see if the drug could shrink tumors in cancers like ovarian, lung, breast, and others. The study was terminated early and enrolled 33 participants to assess safety and initial signs of effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Florida Cancer Specialists
Sarasota, Florida, 34236, United States
-
HonorHealth Research Institute
Scottsdale, Arizona, 85258, United States
-
Institution of Hunan Cancer Hospital
Changsha, Hunan, 410013, China
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
START Mountain Cancer Center
Salt Lake City, Utah, 78229, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.